Han Zhong-chao
National Research Center for Stem Cell Technology and Engineering, Institute of Hematology, CAMS and PUMC, Tianjin 300020, China.
Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2005 Dec;27(6):782-5.
Hematopoietic stem cell (HSC) is the first discovered and well studied tissue stem cell. HSC transplantation has been successfully applied to cure a variety of diseases of hematological and immunological systems. It has long believed that HSC and angioblast come from the common stem cell, the hemangioblast. Recently, HSC has been demonstrated to be able to differentiate into vascular endothelial cells. In animal in vivo models, HSC transplantation can promote angiogenesis and improve limb ischemia. Several pilot clinical studies have shown that transplantation of bone marrow and granulocyte colony stimulating factor mobilized peripheral blood HSC promoted vascular reconstitution in ischemic limbs. Umbilical cord blood has been an important source of HSC for clinical transplantation. Animal studies have demonstrated the efficiency of cord blood HSC transplantation in improving critical limb ischemia. These studies have provided evidences that HSC can be used for the treatment of vascular diseases.
造血干细胞(HSC)是最早被发现且研究充分的组织干细胞。HSC移植已成功应用于治疗多种血液和免疫系统疾病。长期以来人们认为HSC和成血管细胞来源于共同的干细胞——成血管造血干细胞。最近,已证明HSC能够分化为血管内皮细胞。在动物体内模型中,HSC移植可促进血管生成并改善肢体缺血。多项初步临床研究表明,骨髓和粒细胞集落刺激因子动员的外周血HSC移植可促进缺血肢体的血管重建。脐带血一直是临床移植HSC的重要来源。动物研究已证明脐带血HSC移植在改善严重肢体缺血方面的有效性。这些研究提供了证据表明HSC可用于治疗血管疾病。